News

A clinical staff armed with the best clinical decision support (CDS) tools can be a game changer when it comes to improving care quality and reducing care costs.

Rob Danoff, DO, of Aria Health System, explains what should be done to reduce health management costs, while improving care of diabetic patients.

Stroke patients were more adherent to mail order prescriptions versus picking up their medications at retail pharmacies, according to new research presented at the recent International Stroke Conference in Los Angeles, Calif.

Cost issues work their way into medical school curricula

FDA has approved tofacitinib citrate extended-release (Xeljanz XR, Pfizer) tablets for the treatment of moderate to severe rheumatoid arthritis (RA).

FDA approved obinutuzumab (Gazyva, Genentech) for the treatment of certain patients with follicular lymphoma. Here are the top 5 things to know about Gazyva.

Considering entering into a risk-sharing agreement with another payer or provider? Avoid these top mistakes.

In this Q&A, experts discuss how emerging treatments and technologies are affecting diabetes costs.

While there are rumors that President Barack Obama could use his executive authority to regulate drug pricing, analysts say that is not likely. Experts also say that the presidential candidates’ plans to reform skyrocketing drug prices won’t work.

Analysis finds scientific validation of personalized medicine’s ability to improve patient outcomes.

Making the healthcare experience more convenient, effective, and less expensive.

: Proactive pharma tools help CVS manage pharmacy costs and focus on ensuring patients have access to the right drugs at the lowest cost.

A quick progress report on efforts to improve price transparency in the United States, as well as some state-by-state information.

Seniors who regularly took leading heartburn drugs such as Nexium, Prilosec and Prevacid (Takeda Pharmaceuticals) were 44% more likely to end up with dementia, according to a new study.

In one of the biggest drug pricing settlements in history, Pfizer is paying $784.6 million to settle claims alleging that the practices of its Wyeth subsidiary relating to the calculation of Medicaid rebates for Protonix (pantoprazole sodium) violated the Federal Civil False Claims Act and other laws.

Before it hits you, take time to consider effective benefit strategies

FDA has granted breakthrough therapy designation for durvalumab (MEDI4736, AstraZeneca) for the treatment of urothelial bladder cancer.

FDA has approved brivaracetam (Briviact, UCB, Inc.) as an add-on therapy for the treatment of partial onset-seizures in patients with epilepsy.

FDA issued a new guidance recommending that individuals who have been to areas with active Zika virus transmission, who have potentially have been exposed to the virus, or have had a confirmed Zika virus infection should not donate blood. Here are the other top 5 things to know about FDA's new guidelines on Zika blood transmissions.

In the fee-for-service world, physicians need to squeeze in more visits into less time. Here’s how value-based reimbursement is changing the model.

Launching a successful accountable care organization is not easy. Here are some tips from David Swieskowski, MD, MBA, president and chief accountable care officer at Mercy ACO.

FDA declined to approve Merck’s claim that its cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease.

CMS and AHIP, together with physician groups and other stakeholders, announce alignment and simplification of quality measures.

A treatment for community-acquired bacterial pneumonia (CABP) garnered comparable results to moxifloxacin in a newly published late-phase study.

One of the biggest current areas of research is precision medicine, which will transform patient care for generations to come. Here's how one hospital is applying it.

Patients with chronic diseases who received a home visit in HealthPartners’ pilot MTM program reduced readmissions within the first year. Find out how.

A new report found that the majority of state Medicaid programs cannot afford hepatitis C medications, such as Harvoni and Sovaldi (Gilead Sciences), which can cost nearly $100,000 for a single course of treatment.

In another win for biosimilar drugs, FDA staff recently decided that Celltrion and Pfizer’s biosimilar (Remsima) to Johnson & Johnson’s Remicade for rheumatoid arthritis was “highly similar” to the branded drug.